To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential ...

Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

Life sciences companies face an impending “tax policy trifecta” including potential TCJA expiration, U.S. trade and ...

Improvements to the U.S. supply chain are needed to reduce shortages and protect American patients. Industry, academia, ...

Leadership is about fostering the conditions for others to succeed. Empathy shapes how teams function, how trust is built, ...

For many professionals in the drug development industry, cell and gene therapies (CGT) represent a beacon of hope for patients in dire need of innovative treatments. This rapidly evolving field is ...

Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.

QurAlis’ Kasper Roet describes the regulatory hurdles facing the RNA research space in the U.S. and why many companies are pursuing clinical work elsewhere.

QurAlis founder Kasper Roet explains how precision medicine can revolutionize neurogenerative disease therapeutics.